Efficacy and Safety of Nintedanib for the Treatment of Idiopathic Pulmonary Fibrosis: An Update.
Efficacy and Safety of Nintedanib for the Treatment of Idiopathic Pulmonary Fibrosis: An Update.
复制标题
DOI：
10.1007/s40268-017-0221-9
复制
发表时间：
2018-03
期刊：
影响因子：
3
通讯作者：
Rodríguez-Portal JA
中科院分区：
文献类型：
--
作者：
Rodríguez-Portal JA
特发性肺纤维化是一种致命的进行性纤维化间质性肺炎，治疗选择有限。近年来，随着两种新的抗纤维化药物尼达尼布和吡非尼酮的批准，其管理发生了变化。NATIONAL是一种酪氨酸激酶抑制剂，可有效减缓特发性肺纤维化进展，并具有可接受的耐受性。本文综述了尼达尼布在特发性肺纤维化患者中的长期疗效和安全性的新证据。扩展试验的数据表明，尼达尼布可持续减缓疾病进展长达3年，在轻度和重度肺功能损害患者中的疗效相似。尼达尼布治疗可降低急性加重的风险，尼达尼布临床试验数据的综合分析显示死亡率有降低的趋势。Nepal耐受性良好，已被证明安全长达51个月。胃肠道事件，主要是腹泻，是治疗引起的主要不良事件。目前可用的数据证实了其在现实临床环境中的安全性特征，在合并症患者中未发现新的安全性问题。
Idiopathic pulmonary fibrosis is a fatal form of progressive fibrosing interstitial pneumonia with limited treatment options. In recent years, its management has been transformed with the approval of two new antifibrotic drugs: nintedanib and pirfenidone. Nintedanib is a tyrosine kinase inhibitor that efficiently slows idiopathic pulmonary fibrosis progression and has an acceptable tolerability profile. This article reviews new available evidence on the long-term efficacy and safety of nintedanib in patients with idiopathic pulmonary fibrosis. Data from extension trials indicate that nintedanib continues to slow disease progression for up to 3 years and is similarly effective in patients with mild and severe impairment of lung function. Treatment with nintedanib reduces the risk of acute exacerbations, and a combined analysis of data from clinical trials of nintedanib shows a trend towards a reduction in mortality. Nintedanib is well tolerated and has been shown to be safe for up to 51 months. Gastrointestinal events, mainly diarrhoea, are the main adverse events caused by the treatment. Currently available data confirm its safety profile in real-life clinical settings, with no new safety concerns identified in patients with comorbidities.
登录
查看更多内容
影响因子：
10
作者：
Kolb M;Richeldi L;Behr J;Maher TM;Tang W;Stowasser S;Hallmann C;du Bois RM
通讯作者：
du Bois RM
影响因子：
158.5
作者：
Richeldi, Luca;Costabel, Ulrich;du Bois, Roland M.
通讯作者：
du Bois, Roland M.
影响因子：
3.7
作者：
Bonella, Francesco;Kreuter, Michael;Prasse, Antje
通讯作者：
Prasse, Antje
影响因子：
--
作者：
Kreuter M;Bonella F;Wijsenbeek M;Maher TM;Spagnolo P
通讯作者：
Spagnolo P
影响因子：
5
作者：
Wuyts WA;Kolb M;Stowasser S;Stansen W;Huggins JT;Raghu G
通讯作者：
Raghu G